首页 > 最新文献

PharmacoEconomics & Outcomes News最新文献

英文 中文
Monoclonal antibodies in metastatic colorectal cancer: benefits at high cost 单克隆抗体在转移性结直肠癌中的应用:高成本效益
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08244-9
{"title":"Monoclonal antibodies in metastatic colorectal cancer: benefits at high cost","authors":"","doi":"10.1007/s40274-021-08244-9","DOIUrl":"https://doi.org/10.1007/s40274-021-08244-9","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"40 1","pages":"13 - 13"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74424159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SAPIEN 3 TAVI cost effective vs surgical valve replacement for severe aortic stenosis in France SAPIEN 3 TAVI与外科瓣膜置换术治疗严重主动脉瓣狭窄的成本效益比较
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08253-8
{"title":"SAPIEN 3 TAVI cost effective vs surgical valve replacement for severe aortic stenosis in France","authors":"","doi":"10.1007/s40274-021-08253-8","DOIUrl":"https://doi.org/10.1007/s40274-021-08253-8","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"76 1","pages":"22 - 22"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78688516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation therapy cost-effective option for low-risk localised prostate cancer in Australia 澳大利亚低风险局部前列腺癌放射治疗的成本效益选择
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08250-8
{"title":"Radiation therapy cost-effective option for low-risk localised prostate cancer in Australia","authors":"","doi":"10.1007/s40274-021-08250-8","DOIUrl":"https://doi.org/10.1007/s40274-021-08250-8","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"29 1","pages":"19 - 19"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86946727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Direct healthcare costs of patients with dyshidrotic eczema in the USA? 在美国,易湿性湿疹患者的直接医疗费用是多少?
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08237-x
{"title":"Direct healthcare costs of patients with dyshidrotic eczema in the USA?","authors":"","doi":"10.1007/s40274-021-08237-x","DOIUrl":"https://doi.org/10.1007/s40274-021-08237-x","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"22 1","pages":"6 - 6"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80707589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concerns about rollout of inclisiran in primary care in England 对在英格兰初级保健中推出inclisiran的担忧
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08233-x
{"title":"Concerns about rollout of inclisiran in primary care in England","authors":"","doi":"10.1007/s40274-021-08233-x","DOIUrl":"https://doi.org/10.1007/s40274-021-08233-x","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"67 1","pages":"2 - 2"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81128889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population genomic screening of all Australian adults for FH could be cost effective 对所有澳大利亚成年人进行FH人群基因组筛查可能具有成本效益
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08249-9
{"title":"Population genomic screening of all Australian adults for FH could be cost effective","authors":"","doi":"10.1007/s40274-021-08249-9","DOIUrl":"https://doi.org/10.1007/s40274-021-08249-9","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"108 1","pages":"18 - 18"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87586902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaglutide + metformin not cost effective vs empagliflozin + metformin for T2DM in Denmark 在丹麦,对于2型糖尿病,Semaglutide + metformin与恩格列净+ metformin相比没有成本效益
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08254-8
A. cost-utility
{"title":"Semaglutide + metformin not cost effective vs empagliflozin + metformin for T2DM in Denmark","authors":"A. cost-utility","doi":"10.1007/s40274-021-08254-8","DOIUrl":"https://doi.org/10.1007/s40274-021-08254-8","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"4 1","pages":"23 - 23"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90186661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers to prescription drug access within US commercial insurance 美国商业保险中处方药获取的障碍
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08264-7
{"title":"Barriers to prescription drug access within US commercial insurance","authors":"","doi":"10.1007/s40274-021-08264-7","DOIUrl":"https://doi.org/10.1007/s40274-021-08264-7","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"266 1","pages":"33 - 33"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77494443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Willingness to pay for cancer treatments and outcomes: QOL valued similarly to 1-year survival 支付癌症治疗费用的意愿和结果:生活质量与1年生存率相似
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08263-7
{"title":"Willingness to pay for cancer treatments and outcomes: QOL valued similarly to 1-year survival","authors":"","doi":"10.1007/s40274-021-08263-7","DOIUrl":"https://doi.org/10.1007/s40274-021-08263-7","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"16 1","pages":"32 - 32"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74376387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reimbursement and pricing for innovative drugs in France: identifying criteria to inform decision-making 法国创新药物的报销和定价:确定为决策提供信息的标准
Pub Date : 2021-12-01 DOI: 10.1007/s40274-021-08251-8
{"title":"Reimbursement and pricing for innovative drugs in France: identifying criteria to inform decision-making","authors":"","doi":"10.1007/s40274-021-08251-8","DOIUrl":"https://doi.org/10.1007/s40274-021-08251-8","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"06 1","pages":"20 - 20"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86356327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
PharmacoEconomics & Outcomes News
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1